Is LYNPARZA (Olaparib) right for you?

LYNPARZA in combination with abiraterone and prednisone or prednisolone may be for you:

If your prostate cancer is metastatic, which means it has spread to other parts of your body
If your prostate cancer no longer responds to treatment that lowers testosterone (castration resistant)
If you have a certain type of abnormal inherited or acquired BRCA mutation

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

If your prostate cancer has certain HRR (homologous recombination repair) gene mutations
If your prostate cancer is metastatic, which means it has spread to other parts of your body, and no longer responds to treatment that lowers testosterone (castration resistant)
If your cancer has progressed after prior treatment with certain hormone therapies, enzalutamide or abiraterone

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

Top 5 Most Common Side Effects:

Nausea: Occurs in approximately 60% to 77% of patients.
Fatigue (Tiredness) or Weakness: Reported by about 55% to 67% of patients.
Anemia (Low Red Blood Cell Counts): Experienced by approximately 36% to 46% of patients.
Vomiting: Occurs in about 32% to 40% of patients.
Diarrhea: Reported by approximately 24% to 34% of patients.

Top 5 Most Serious Side Effects:

Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): These are rare but serious bone marrow disorders that have been reported in a small number of patients. The exact incidence is not well-defined but is considered uncommon.
Pneumonitis (Lung Inflammation): This is an uncommon but serious side effect. The exact incidence rate is not specified but is considered rare.
Blood Clots (Venous Thromboembolism): Some patients may develop blood clots, including deep vein thrombosis or pulmonary embolism. The exact incidence is not specified but is considered uncommon.
Severe Bone Marrow Suppression: This can lead to significantly low blood cell counts, increasing the risk of infections, anemia, or bleeding. The exact incidence is not specified but is considered uncommon.
Severe Allergic Reactions: While rare, severe allergic reactions can occur. The exact incidence is not specified but is considered rare.

Genetic Testing: Lynparza is most effective in patients with specific BRCA1/BRCA2 mutations or other homologous recombination repair (HRR) gene mutations. Genetic testing is crucial to determine if you carry these mutations.
Cancer Type and Stage: Lynparza is typically used in advanced or metastatic cancers that have progressed after other treatments.
Previous Treatments: Your eligibility may depend on the therapies you’ve already tried, such as chemotherapy or hormone therapy.
Side Effects Tolerance: Lynparza can have significant side effects, including nausea, fatigue, anemia, and, rarely, severe complications like myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Willingness to Monitor: Regular blood tests and follow-ups are required while taking Lynparza to monitor your blood counts and ensure no serious side effects develop.

Individuals without relevant genetic mutations (e.g., BRCA1/BRCA2 or HRR mutations) may not benefit significantly from Lynparza.
Patients with certain health conditions (e.g., severe liver or kidney impairment) may need to avoid Lynparza or use it with caution.
Pregnant or breastfeeding individuals should not use Lynparza due to potential harm to the fetus or infant.